Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 4/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL3251016 | 1.00 | GSK3B (0.58) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL4446059 | 0.98 | GSK3B (0.60) | GSK3BCASP3CASP2CASP7CASP6 | |
| Tetraethylene Glycol SCHEMBL8058824 | 0.92 | GSK3B (0.48) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL8058821 | 0.86 | GSK3B (0.43) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL2452324 | 0.83 | GSK3B (0.75) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL10495310 | 0.78 | GSK3B (0.65) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL10496306 | 0.78 | GSK3B (0.65) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL5215747 | 0.77 | GSK3B (0.71) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalic Anhydride SCHEMBL185274 | 0.76 | ALOX15 (0.58) | GAAMEN1KMT2AMAPK1TSHR | |
| Phthalimide SCHEMBL29366030 | 0.76 | GSK3B (1.00) | GSK3BCASP3CASP2CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071737-B2 | Nucleic acid ligand complexes | Glead Sciences, Inc. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2168973-A1 | Nucleic acid ligand complexes | Gilead Sciences, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-0824541-B1 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-0824541-A4 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-0957929-B1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2006-02-22 | — | — | EP | disclosed |
| US-6962784-B2 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050164974-A1 | Nucleic acid ligand complexes | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| US-20030125263-A1 | Nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2003-07-03 | — | — | US | disclosed |
| US-6465188-B1 | PARTITIONING, GENETIC REPLICATION; SELEX | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6426335-B1 | ADMINISTERING COMPLEX OF NUCLEIC ACID LIGAND | GILEAD SCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6147204-A | COMPLEX FOR TARGETING THERAPEUTIC OR DIAGNOSTIC AGENTS TO PREFERENTIAL BIOLOGICAL TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-1015629-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | Proligo L.L.C. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5859228-A | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998030720-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0824541-A1 | NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034876-A1 | NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | TLR9, SNRPE, HAVCR2 | GSK3B 4587/4885CASP3 1819/4885CASP2 2227/4885 |
| US-20050164974-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | GSK3B 4587/4885CASP3 1819/4885CASP2 2227/4885 |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | GSK3B 4288/4885CASP3 2039/4885CASP2 2238/4885 |
| US-20030125263-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | GSK3B 4587/4885CASP3 1819/4885CASP2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.